bearish

Betta Pharma (贝达医药) A+H: Tier 2 Player Struggled to Break Out

339 Views18 Feb 2021 15:50
The company has a comprehensive range of small molecule product candidates covering lung cancer but is short of the truly innovative drugs.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Ke Yan, CFA, FRM
Asia Pac IPO & Placement Research, China biotech
Aequitas Research
EquitiesEquity Capital MarketsQuantitative Analysis
Price Chart(Sign Up to Access)
analytics-chart
  • Betta Pharma (贝达医药) A+H: Tier 2 Player Struggled to Break Out
    18 Feb 2021
x